Rib-X Counting On Rational Drug Design To Outsmart Resistant Bacteria

Three years after creating its RX-04 discovery platform, Rib-X Pharmaceuticals Inc. has vetted 1,400 compounds, tuned them for efficacy against multi-drug resistant bacteria, and is in the process of selecting a handful of candidates to prep for an IND in 2012.